p38-MAPK

Cat. No.

A40761

CAS No.

581098-48-8

p38 MAP Kinase Inhibitor III

p38 MAP Kinase Inhibitor III is a potent inhibitor of p38 MAPK, with an IC50 value of 0.9 μM. This compound also effectively reduces the release of pro-inflammatory cytokines, specifically IL-1β and TNF-α, with IC50 values of 0.37 μM and 0.044 μM, respectively. p38 MAP Kinase Inhibitor III is valuable for research in inflammation, signaling pathways, and related therapeutic applications.

Cat. No.

A40762

CAS No.

765914-60-1

Emprumapimod

Synonyms: PF-07265803

Emprumapimod is a selective inhibitor of p38α MAPK that exhibits potent oral activity. By directly inhibiting LPS-induced IL-6 production in RPMI-8226 cells (IC50=100 pM), it presents significant anti-inflammatory properties. This compound is applicable in research studies focused on dilated cardiomyopathy and acute inflammatory pain, making it a valuable tool for elucidating the role of p38α in various inflammatory conditions.

Cat. No.

A40766

CAS No.

1095003-80-7

p38α inhibitor 2

p38α Inhibitor 2 is a highly selective inhibitor of the p38α mitogen-activated protein kinase (MAPK), exhibiting a pIC50 value of 9.6. This compound demonstrates potent inhibition of the hERG ion channel with an IC50 of 27 μM. Additionally, p38α Inhibitor 2 shows an excellent selectivity profile, demonstrating less than 30% inhibition across a panel of 51 protein kinases at a concentration of 10 μM, indicating its potential utility in various biological research applications focused on inflammation and stress responses.

Cat. No.

A40768

CAS No.

1670-87-7

SD-169

SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, exhibiting an IC50 of 3.2 nM. This compound also demonstrates weak inhibition of p38β MAPK with an IC50 of 122 nM. SD-169 has been shown to impede the development and progression of diabetes by inhibiting T cell infiltration and activation, making it valuable for research in immunology and metabolic disease pathways.

Cat. No.

A40769

CAS No.

219138-24-6

p38 MAPK-IN-4

p38 MAPK-IN-4 is a selective inhibitor of p38 mitogen-activated protein kinase (MAPK) with an IC50 of 35 nM. This compound modulates the p38 MAPK signaling pathway, which is critical in cellular responses to stress and inflammation. It is suitable for research applications investigating inflammatory diseases, cancer, and other conditions associated with p38 MAPK activity.

Cat. No.

A40770

CAS No.

1590403-33-0

GDC-3280

Synonyms: AK3287; AKEX0011

GDC-3280 is an orally active anti-inflammatory and anti-fibrotic agent that operates primarily through the inhibition of the ASK1-p38 MAPK pathway. It effectively mitigates the inflammatory and fibrotic responses associated with silicosis and influences macrophage polarization. GDC-3280 is a valuable tool for research aimed at understanding and developing therapeutic strategies for inflammatory and fibrotic diseases.

Cat. No.

A40771

CAS No.

1638-41-1

p38 MAP Kinase Inhibitor IV

p38 MAP Kinase Inhibitor IV is a selective ATP-competitive inhibitor targeting p38α MAPK, exhibiting IC50 values of 0.13 μM and 0.55 μM for p38α and p38β MAPK, respectively. This compound plays a crucial role in modulating cellular responses to stress and inflammation by inhibiting the p38 MAPK signaling pathway. It is utilized in research applications focused on therapeutic interventions for inflammatory diseases and various cancer models.

Cat. No.

A40773

CAS No.

66778-17-4

Esculin sesquihydrate

Esculin sesquihydrate is a coumarin glucoside that serves as an inhibitor of p38 MAPK. This compound has demonstrated significant biological activity in ameliorating cognitive impairment associated with experimental diabetic nephropathy. Additionally, esculin sesquihydrate exhibits antioxidant and anti-inflammatory properties, primarily through modulation of the MAPK signaling pathway, making it valuable for research in diabetes-related complications and inflammation studies.

Cat. No.

A40775

CAS No.

2550399-06-7

NR-7h

NR-7h is a selective degrader of p38α and p38β, exhibiting DC50 values of 24 nM and 27.2 nM for p38α in T47D and MB-MDA-231 cells, respectively. This compound effectively induces degradation of these kinases, facilitating the study of their roles in cellular signaling pathways. NR-7h is applicable in cancer research and other studies investigating inflammatory responses and signal transduction mechanisms.

Cat. No.

A40777

CAS No.

1056164-52-3

PF-03715455

PF-03715455 is a selective p38 MAPK inhibitor with significant potency, demonstrating IC50 values of 0.88 nM for p38α and 23 nM for p38β. This compound effectively inhibits LPS-induced TNFα production in human whole blood, with an IC50 of 1.7 nM. PF-03715455 has potential applications in research focusing on chronic obstructive pulmonary disease (COPD) and inflammation-related pathways.

Cat. No.

A40778

CAS No.

2771319-74-3

SR-302

SR-302 is a selective DDR/p38 inhibitor that exhibits potent biological activity with IC50 values of 0.125 μM for p38α, 0.023 μM for DDR1, and 0.018 μM for DDR2. This compound is valuable for investigating fibrotic disorders, including renal and pulmonary fibrosis, atherosclerosis, and various types of cancer. SR-302 serves as a key tool for elucidating the roles of DDR and p38 signaling pathways in disease progression and therapeutic intervention.

Cat. No.

A40779

CAS No.

380645-50-1

LX-3

LX-3 is a selective inhibitor of the p38 MAPK signaling pathway. It effectively modulates gene expression by reactivating silenced EGFP reporter genes associated with DNA methylation, including TNF, EGR1, LY6K, and ISG20. This reagent is valuable for studies investigating the roles of p38 MAPK in cellular processes and the impact of DNA methylation on gene regulation.

Cat. No.

A40780

CAS No.

2550397-96-9

p38α inhibitor 5

p38α inhibitor 5 is a PROTAC-type ligand that specifically targets p38α MAP kinase. This compound is designed to facilitate the degradation of p38α, providing a valuable tool for studying the enzyme's role in cellular signaling and inflammation. It is suitable for applications in drug discovery and therapeutic research, particularly in the context of conditions associated with p38α dysregulation.

Cat. No.

A40781

CAS No.

755753-89-0

Org 48762-0

Synonyms: UR13870

Org 48762-0 is a selective p38 inhibitor, exhibiting a potent EC50 of 0.1 μM for p38α kinase. This compound demonstrates a high degree of specificity for both p38α and p38β over other kinases, allowing for targeted therapeutic interventions. Org 48762-0 effectively reduces lipopolysaccharide-induced TNFα release, making it a valuable tool in the study of inflammatory diseases. Its applications extend to researching conditions such as rheumatoid arthritis and Werner syndrome.

Cat. No.

A40784

CAS No.

153127-42-5

Cyclocurcumin

Cyclocurcumin is a potent inhibitor of p38α, a key signaling molecule involved in inflammatory responses. It demonstrates significant antirheumatic, antivasoconstrictive, and antioxidant activities. This compound is valuable for research applications focused on inflammation, cardiovascular diseases, and oxidative stress.

Cat. No.

A40785

CAS No.

1474022-02-0

PF-05381941

PF-05381941 is a potent dual inhibitor of TAK1 and p38α, exhibiting IC50 values of 156 nM and 186 nM, respectively. This compound effectively modulates the MAPK signaling pathway, making it a valuable tool for investigating cellular responses to stress and inflammation. PF-05381941 is commonly utilized in research focused on cancer, autoimmune diseases, and other pathological conditions linked to dysregulated kinase activity.

Cat. No.

A40787

CAS No.

249937-52-8

RO3201195

RO3201195 is a selective inhibitor of p38 MAPK, a key signaling molecule involved in inflammatory responses and cellular stress. This compound demonstrates potent inhibition of WS cell proliferation, with an IC50 value of 190 nM. RO3201195 is suitable for research applications aimed at understanding the role of p38 MAPK in various biological processes, including inflammation and cancer.

Cat. No.

A40794

CAS No.

2170888-41-0

2-Oleoxyphenethyl phosphocholin

2-Oleoxyphenethyl phosphocholin is an inhibitor of the p38 MAPK pathway, which plays a critical role in cellular stress responses and inflammatory processes. This compound exhibits significant anticancer activity, potentially through its interaction with the lipid-binding pocket of p38 MAPK. Its broad-spectrum anti-tumor properties make 2-Oleoxyphenethyl phosphocholin a valuable tool for research in cancer biology and therapeutic development.

Cat. No.

A40801

CAS No.

2396754-57-5

p38-α MAPK-IN-4

p38-α MAPK-IN-4 is a selective inhibitor of p38α MAPK, exhibiting an IC50 value of 1.5 µM. This compound demonstrates significant efficacy in the prevention of mechanical allodynia in vivo, making it a valuable tool for research into pain mechanisms and inflammatory responses. Its specificity and potency render it suitable for investigating the role of p38α MAPK in various biological contexts, including neurobiology and chronic pain studies.

Cat. No.

A40803

CAS No.

1357621-20-5

p38α-IN-11

P38α-IN-11 is a selective inhibitor of p38α, exhibiting a KD value of 586 nM. This compound is primarily utilized in research investigating cervical cancer, enabling studies on the modulation of p38α signaling pathways and their implications in tumorigenesis. Its inhibitory effects make it a valuable tool for elucidating the role of p38α in cancer biology.

Cat. No.

A40805

CAS No.

13142-47-7

p38 Kinase inhibitor 4

p38 Kinase Inhibitor 4 is a selective inhibitor of p38 mitogen-activated protein kinase (MAPK), which plays a crucial role in mediating cellular responses to stress and inflammation. This compound demonstrates significant anti-inflammatory activity, making it valuable for research in inflammation-related diseases and cellular signaling pathways. It serves as an essential tool for studying p38 MAPK's role in such processes and evaluating potential therapeutic strategies.

Cat. No.

A40806

CAS No.

180869-17-4

p38 MAPK-IN-9

p38 MAPK-IN-9 is a selective inhibitor of p38α mitogen-activated protein kinase (MAPK), demonstrating an IC50 value of 9.6 nM. This compound exhibits potent anti-inflammatory activity, making it a valuable tool for research into inflammatory diseases, including rheumatoid arthritis, septic shock, and chronic obstructive pulmonary disease (COPD). Its oral bioavailability and high selectivity position p38 MAPK-IN-9 as an effective reagent for exploring the role of p38 MAPK in various biological pathways and therapeutic interventions.

Cat. No.

A40808

CAS No.

851845-37-9

AZD 6703

AZD 6703 is a selective inhibitor of p38α MAP kinase, targeting the MAPK pathway involved in inflammatory responses. It demonstrates significant anti-inflammatory activity, making it a valuable tool for investigating inflammatory diseases and related therapeutic interventions. Researchers can utilize AZD 6703 to explore p38 MAPK's role in various cellular processes and to develop strategies for modulating inflammation.

Cat. No.

A40810

CAS No.

188352-45-6

L-167307

L-167307 is a potent p38 kinase inhibitor that exhibits anti-inflammatory properties. It has been shown to significantly reduce secondary paw swelling in rat models of adjuvant-induced arthritis. This compound is valuable for research applications involving inflammation and pain pathways, facilitating the study of p38-mediated signaling in various disease models.

Cat. No.

A40813

CAS No.

2418614-81-8

PLK1/p38γ-IN-1

PLK1/p38γ-IN-1 is a multitarget inhibitor that selectively targets PLK1 and p38γ kinases. This compound has demonstrated the ability to inhibit cell proliferation in human hepatocellular carcinoma and hepatoblastoma cell lines in vitro. PLK1/p38γ-IN-1 is valuable for research focused on cancer biology and the modulation of cell cycle pathways.